//

China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2012

FY12 Total Sales Up 20.7% to $184.8 Million

FY12 Operating Margin Reaching 40.3%

FY12 Non-GAAP Net Income Up 31.5% to $48.0 Million

PR Newswire
BEIJING
Mar 13, 2013

BEIJING, March 13, 2013 /PRNewswire-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year 2012.

Fourth Quarter 2012 Financial Highlights

    --  Total sales in the fourth quarter of 2012 decreased by 4.6% to $34.0
        million from $35.7 million in the same quarter of 2011.
    --  Gross profit decreased by 5.2% to $23.9 million from $25.2 million in
        the same quarter of 2011. Gross margin decreased to 70.4% in the fourth
        quarter of 2012 from 70.8% in the fourth quarter of 2011.
    --  Income from operations increased by 41.5% to $13.9 million from $9.8
        million in the same quarter of 2011. Operating margin increased to 41.0%
        in the fourth quarter of 2012 from 27.6% in the same quarter of 2011.
    --  Net income attributable to the Company increased by 25.3% to $5.8
        million from $4.6 million in the same quarter of 2011. Fully diluted net
        income per share was $0.21 in the fourth quarter of 2012 as compared to
        $0.18 in the same quarter of 2011.
    --  Non-GAAP adjusted net income attributable to the Company was $7.3
        million, representing a 15.6% decrease from $8.6 million in the same
        quarter of 2011. Non-GAAP adjusted net income per share was $0.27,
        compared to $0.33 in the same quarter of 2011.

Fiscal Year 2012 Financial Highlights

    --  Total sales in 2012 increased by 20.7% to $184.8 million from $153.1
        million in 2011.
    --  Gross profit in 2012 increased by 17.7% to $126.0 million from $107.1
        million in 2011. Gross margin decreased to 68.2% in 2012 from 69.9% in
        2011.
    --  Income from operations in 2012 increased by 131.2% to $74.5 million from
        $32.2 million in 2011. Operating margin increased to 40.3% in 2012 from
        21.0% in 2011.
    --  Net income attributable to the Company increased by 148.7% to $45.2
        million from $18.2 million in 2011. Fully diluted net income per share
        was $1.62 in 2012 as compared to $0.37 in 2011.
    --  Non-GAAP adjusted net income attributable to the Company was $48.0
        million, representing a 31.5% increase from $36.5 million in 2011.
        Non-GAAP adjusted net income per share was $1.79, compared to $1.37 in
        2011.

Mr. David (Xiaoying) Gao, Chairman and Chief Executive Officer of China Biologic, commented, "We're pleased to see consistently strong demand for our products throughout 2012, which allowed us to enjoy steady top-line annual growth. Our effort over recent years in expanding our sales force and focusing on direct sales to hospitals and inoculation centers has bolstered aspects of our pricing power and reduced our reliance on distributors. We also implemented additional cost control measures since the second half of 2012, resulting in lower selling expenses as a percentage of total sales. Additionally, thanks to enhanced corporate management initiatives, accounts receivable decreased 33.1% year-over-year. Inventories increased 6.1%, in line with production expansion.

"In response to the previously announced delay in construction of our new production facility in Guizhou due to slower-than-expected government approval of land use rights, we implemented an alternative strategy to commence upgrading our current production facility at Guizhou Taibang in June or July 2013 to meet the more stringent Good Manufacturing Practice ("GMP") standards that take effect by year end. We expect the comprehensive upgrading to our Guizhou Taibang facility to take six to nine months, during which time we will suspend production at this facility. We expect the upgrade of the production facility will be complete in the first half of 2014. To mitigate the negative impact on sales and ensure supply continuity, we have been increasing inventory levels in the past few quarters, adjusting product shipment plans for 2013, and have been and will continue to increase production volume during the first half of 2013."

Mr. Gao continued, "We are also pleased to announce that in January 2013, Shandong Taibang obtained approval from local authorities to establish a new plasma collection station in Cao County, Shandong Province. We expect to obtain operating permits and commence plasma collection operations by the end of June 2013. Cao County is home to a population of 1.6 million and we expect our new plasma station there to ramp up in the next three years, potentially enlarging our collection base in Shandong by 10 to 15 percent."

Fourth Quarter 2012 Financial Performance

Total sales in the fourth quarter of 2012 were $34.0 million, representing a decrease of 4.6% from $35.7 million in the same quarter of 2011. The decrease was mainly due to a human immunoglobulin for intravenous injection ("IVIG") products shipment delay in October when the Company appealed to various regional governments for favorable pricing policies following a price adjustment announcement by the Chinese National Development and Reform Commission ("NDRC") in September 2012. Guizhou and Shandong provincial governments accepted our appeals and approved to lift the tender price ceilings for IVIG products in late October.

Income from operations increased by 41.5% to $13.9 million from $9.8 million in the same quarter of 2011, mainly due to $3.5 million decrease in selling expenses. Operating margin increased to 41.0% in the fourth quarter of 2012 from 27.6% in the same quarter of 2011.

Net income attributable to the Company increased by 25.3% to $5.8 million from $4.6 million in the same quarter of 2011. Fully diluted net income per share was $0.21 in the fourth quarter of 2012 compared to $0.18 in the same quarter of 2011.

Non-GAAP adjusted net income attributable to the Company was $7.3 million, or $0.27 per diluted share, in the fourth quarter of 2012, representing a 15.6% decrease from $8.6 million, or $0.33 per diluted share, in the fourth quarter of 2011. In the fourth quarter of 2011, the Company recorded a loss from change in fair value of warrants of $3.1 million, while no such loss was recorded in the same quarter of 2012.

Fiscal Year 2012 Financial Performances

Total sales in 2012 were $184.8 million, an increase of 20.7% from $153.1 million in 2011. Excluding foreign exchange influence, the increase in sales was primarily attributable to a mix of price and volume increases in plasma-based products, as well as a substantial increase in sales of placenta polypeptide products.

During 2012, most of the Company's approved products recorded price increases. The general price increases for the human albumin products and immunoglobulin product group (other than human hepatitis B immunoglobulin products) were primarily attributable to strong market demand and a shortage of supply following the closure of several plasma collection stations in Guizhou in 2011.

During 2012, human albumin products and human immunoglobulin for intravenous injection ("IVIG") products remained the largest two sales contributors.

    --  As a percentage of total sales, human albumin product revenue was 44.6%
        in 2012 as compared to 54.5% in 2011. Sales volume of human albumin
        products declined 9.2% over the year.
    --  As a percentage of total sales, IVIG revenue was 39.0% in 2012 as
        compared to 32.3% in 2011. Sales volume of IVIG products increased by
        33.6% over the year, mainly due to increased market demand and the
        Company's ability to ship more product as a result of increased
        inventory levels built up in the later part of 2011 in anticipation of
        the demand increase.

Cost of sales increased by 27.9% to $58.8 million in 2012 from $46.0 million in 2011. Cost of sales as a percentage of total sales was 31.8%, as compared to 30.1% in 2011. Volume and percentage increases in cost of sales were mainly due to increased sales activities and increased raw plasma collection costs resulting from higher compensation paid to plasma donors. Gross profit increased by 17.7% to $126.0 million in 2012 from $107.1 million in 2011. Gross margin decreased slightly to 68.2% in 2012 from 69.9% in 2011.

Total operating expenses in 2012 decreased by 31.2% to $51.5 million from $74.9 million in 2011, primarily due to decreased impairment loss. The Company incurred an impairment loss of $24.8 million in 2011, for both goodwill and abandonment of long-lived assets as a result of the closure of several plasma collection stations in Guizhou. There was no impairment loss in 2012. As a percentage of total sales, total operating expenses decreased to 27.9% in 2012 from 48.9% in 2011.

Selling expenses in 2012 decreased to $14.4 million from $14.6 million in 2011. As a percentage of total sales, selling expenses was 7.8%, down from 9.5% in 2011. The decrease in selling expenses as a percentage of sales was primarily due to favorable product pricing and less reliance on distributors as a result of the Company's lengthy efforts at expanding its sales force as well as the Company's sales strategy of focusing on direct sales to hospitals and inoculation centers. The Company has taken additional steps to further control selling expenses since the second half 2012.

General and administrative expenses in 2012 increased by 8.0% to $34.0 million from $31.5 million in 2011. As a percentage of total sales, general and administrative expenses was 18.4% in 2012, down from 20.6% in 2011. The increase in G&A expenses was mainly due to higher payroll expenses and employee benefits, as well as legal expenses related to the disputes among Guizhou Taibang shareholders over the additional capital.

Research and development expenses in 2012 were $3.0 million, as compared to $4.0 million in 2011, representing a decrease of 23.8%. As a percentage of total sales, research and development expenses for the years ended December 31, 2012 and 2011 were 1.6% and 2.6%, respectively. The decrease in R&D expenses was primarily due to the completion of the R&D tests on human coagulation factor VIII ("FVIII") in early 2012.

Income from operations for the year ended December 31, 2012 was $74.5 million, an increase of 131.2% from $32.2 million in the same period of 2011. Operating margin increased to 40.3% in 2012 from 21.0% in 2011.

Income tax expense in 2012 was $15.2 million, as compared to $10.9 million in 2011. The effective income tax rates were 18.7% and 25.8% for the twelve months ended December, 2012 and 2011, respectively.

Net income attributable to the Company increased by 148.7% to $45.2 million in 2012, from $18.2 million in 2011. Net margins were 24.5% and 11.9% for the year ended December 31, 2012 and 2011, respectively. Fully diluted net income per share was $1.62 for the year ended December 31, 2012, as compared to $0.37 for the year ended December 31, 2011.

Non-GAAP adjusted net income attributable to the Company was $48.0 million or $1.79 per diluted share for the year ended December 31, 2012, representing a 31.5% increase from $36.5 million or $1.37 per diluted share in 2011.

Non-GAAP adjusted net income and diluted earnings per share in 2012 excluded an aggregate $1.8 million gain related to the change in the fair value of derivative liabilities, and $4.5 million of non-cash employee share-based compensation expenses.

As of December 31, 2012, the Company had cash and cash equivalents of $129.6 million, compared to $89.4 million as of December 31, 2011.

Net cash provided by operating activities for the year ended December 31, 2012 was $71.1 million, as compared to $38.5 million for the year 2011.

Outlook

For the full year of 2013, the Company expects total sales to be in the range of $195 million to $205 million. This guidance assumes, the production suspension at the Company's Guizhou facility, only organic growth and excludes acquisitions and necessarily assumes no significant adverse price changes during 2013. The Company estimates full year non-GAAP adjusted net income to be in the range of $50 million to $53 million.

This forecast reflects the Company's current and preliminary views, which are subject to change.

Conference Call

The Company will host a conference call at 8:00 am, Eastern Time on Thursday, March 14, 2013, which is 8:00 pm, Beijing Time on March 14, 2013, to discuss fourth quarter and fiscal year 2012 results and answer questions from investors. Listeners may access the call by dialing:


    US:                             +1 866 978 9970

    International:                   +852 3027 5500

    Hong Kong:                            3027 5500

    China Domestic:                    800 803 6103

    China Domestic Mobile:             400 681 6405


    Passcode:              674 477#

A telephone replay of the call will be available after the conclusion of the conference all through 11:59 pm, Eastern Time on March 20, 2012. The dial-in details are:


    US:                      +1 866 753 0743

    International:            +852 3027 5520

    Hong Kong:                     3027 5520

    China Domestic:             800 876 5016


    Passcode:       138 012#

About China Biologic Products, Inc.

China Biologic Products, Inc. (Nasdaq: CBPO), is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 plasma-based products through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com.

Non-GAAP Disclosure

This news release contains non-GAAP financial measures that exclude non-cash compensation expenses related to options granted to employees and directors under the Company's 2008 Equity Incentive Plan and changes in the fair value of derivative liabilities, including warrants and derivative instruments (including the conversion option) embedded in the Company's Senior Secured Convertible Notes (after adding back interest related to the convertible notes under the if-converted method). To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information excluding the impact of these items in this release. The Company's management believes that these non-GAAP measures provide investors with a better understanding of how the results relate to the Company's historical performance. A reconciliation of the adjustments to GAAP results appears in the table accompanying this news release. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies.

Safe Harbor Statement

This news release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein, are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect.

Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including its potential inability to achieve the expected operating and financial performance in 2013, potential inability to find alternative sources of plasma, potential inability to increase production at permitted sites, potential inability to mitigate the financial consequences of a temporarily reduced raw plasma supply through cost cutting or other efficiencies, and potential additional regulatory restrictions on its operations and those additional risks and uncertainties discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Contact:

China Biologic Products, Inc.
Mr. Ming Yin
Vice President
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com

ICR Inc.
Mr. Bill Zima/Rob Koepp
Phone: +86-10-6583-7511 or +1-646-405-5191
E-mail: william.zima@icrinc.com

Financial statements follow


                                                       CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

                                             AUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME


                                                   For the Years Ended
                                                   -------------------

                                          December 31,                                               December 31,             December 31,

                                                             2012                                                       2011                     2010
                                                             ----                                                       ----                     ----

    Sales                                            $184,813,495                                               $153,092,289             $139,695,417

    Cost of sales                                      58,835,998                                                 46,017,661               36,951,149
                                                       ----------                                                 ----------               ----------

    Gross profit                                      125,977,497                                                107,074,628              102,744,268


    Operating expenses

           Selling expenses                            14,421,258                                                 14,595,794                7,372,348

           General and administrative
            expenses                                   34,034,360                                                 31,519,824               24,467,495

           Research and development
            expenses                                    3,032,719                                                  3,978,233                2,336,126

           Impairment loss of goodwill                          -                                                 18,160,281                        -

           Loss on abandonment and write-
            off of long-lived assets                            -                                                  6,603,028                        -
                                                              ---                                                  ---------                      ---

    Income from operations                             74,489,160                                                 32,217,468               68,568,299

    Other income (expenses)

           Equity in income of an equity
            method investee                             2,665,881                                                  1,858,171                1,070,241

           Change in fair value of
            derivative liabilities                      1,769,140                                                 11,974,834               (3,233,288)

           Interest income                              2,910,297                                                  1,356,950                  752,317

           Interest expense                            (1,269,850)                                                (4,670,606)              (2,682,482)

           Other income (expense), net                    570,511                                                   (453,949)               1,125,972
                                                          -------                                                   --------                ---------

    Total other income (expenses),
     net                                                6,645,979                                                 10,065,400               (2,967,240)


    Earnings before income tax
     expense                                           81,135,139                                                 42,282,868               65,601,059


    Income tax expense                                 15,163,147                                                 10,899,513               13,608,755
                                                       ----------                                                 ----------               ----------


    Net income                                         65,971,992                                                 31,383,355               51,992,304


    Less: Net income attributable to
     noncontrolling interest                           20,749,803                                                 13,201,645               20,449,421
                                                       ----------                                                 ----------               ----------


    Net income attributable to China
     Biologic Products, Inc.                          $45,222,189                                                $18,181,710              $31,542,883
                                                      -----------                                                -----------              -----------


    Net income per share of common
     stock:

           Basic                                            $1.73                                                      $0.73                    $1.34
                                                            -----                                                      -----                    -----

           Diluted                                          $1.62                                                      $0.37                    $1.30
                                                            -----                                                      -----                    -----

    Weighted average shares used in
     computation:

           Basic                                       26,153,540                                                 25,028,796               23,586,506

           Diluted                                     26,839,723                                                 26,654,662               24,176,432


    Net income                                        $65,971,992                                                $31,383,355              $51,992,304


    Other comprehensive income :

    Foreign currency translation
     adjustment, net of nil income
     taxes                                              1,735,492                                                  6,846,721                5,177,515
                                                        ---------                                                  ---------                ---------


    Comprehensive income                               67,707,484                                                 38,230,076               57,169,819


    Less: Comprehensive income
     attributable to noncontrolling
     interest                                          21,163,655                                                 15,320,805               21,831,352
                                                       ----------                                                 ----------               ----------


    Comprehensive income
     attributable to China Biologic
     Products, Inc.                                   $46,543,829                                                $22,909,271              $35,338,467
                                                      -----------                                                -----------              -----------


                                                  CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

                                                   AUDITED CONDENSED CONSOLIDATED BALANCE SHEETS


                                                 December 31,                                    December 31,

                                                         2012                                            2011
                                                         ----                                            ----

    ASSETS

    Current Assets

       Cash and cash equivalents                                                  $129,609,317                 $89,411,835

       Accounts receivable, net of
        allowance for doubtful accounts                                             11,206,244                  16,757,368

       Inventories                                                                  75,679,173                  71,338,590

       Prepayments and other current
        assets                                                                       5,664,919                   6,185,720
                                                                                     ---------                   ---------

             Total Current Assets                                                  222,159,653                 183,693,513


    Property, plant and equipment, net                                              51,325,177                  43,329,463

    Intangible assets, net                                                           3,541,582                   6,520,671

    Land use rights, net                                                             5,818,709                   5,487,343

    Deposits related to land use rights                                             14,752,574                   1,504,568

    Restricted cash                                                                  2,912,145                           -

    Equity method investment                                                        10,537,310                   8,357,017
                                                                                    ----------                   ---------

               Total Assets                                                       $311,047,150                $248,892,575
                                                                                  ------------                ------------


    LIABILITIES AND STOCKHOLDERS'
     EQUITY

    Current liabilities

       Short-term bank loans                                                        $7,935,000                 $11,018,000

       Accounts payable                                                              2,908,624                   4,996,463

       Due to related parties                                                        4,081,624                   3,319,938

       Other payables and accrued expenses                                          25,423,349                  32,851,707

       Advance from customers                                                        2,857,420                   4,852,125

       Income tax payable                                                            4,513,075                   5,373,633

       Derivative liabilities -warrants                                                      -                   5,410,419
                                                                                           ---                   ---------

             Total Current Liabilities                                              47,719,092                  67,822,285

    Deferred income                                                                  2,912,145                           -

    Other liabilities                                                                2,996,749                   2,029,249
                                                                                     ---------                   ---------

             Total Liabilities                                                      53,627,986                  69,851,534
                                                                                    ----------                  ----------


    Stockholders' Equity

       Common stock: par value $0.0001;
        100,000,000 shares authorized;
        26,629,615 and 25,601,125 shares
        issued and outstanding at December
        31, 2012 and 2011, respectively                                                  2,663                       2,560

       Additional paid-in capital                                                   62,251,731                  48,838,311

       Retained earnings                                                           119,143,000                  73,920,811

       Accumulated other comprehensive
        income                                                                      14,072,322                  12,750,682
                                                                                    ----------                  ----------

       Total equity attributable to China
        Biologic Products, Inc.                                                    195,469,716                 135,512,364


       Noncontrolling interest                                                      61,949,448                  43,528,677


             Total Stockholders' Equity                                            257,419,164                 179,041,041
                                                                                   -----------                 -----------


       Commitments and contingencies                                                         -                           -


             Total Liabilities and Stockholders'
              Equity                                                              $311,047,150                $248,892,575
                                                                                  ------------                ------------


                                                                                          CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

                                                                                      AUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS


                                                                                                                                           For the Years Ended

                                                                                                                                  December 31,                   December 31,               December 31,

                                                                                                                                                     2012                           2011                       2010
                                                                                                                                                     ----                           ----                       ----

    CASH FLOWS FROM OPERATING ACTIVITIES:

    Net income                                                                                                                                $65,971,992                    $31,383,355                $51,992,304

    Adjustments to reconcile net income to net cash provided by operating activities:

             Depreciation                                                                                                                       5,792,418                      4,253,661                  3,607,184

             Impairment loss of goodwill                                                                                                                -                     18,160,281                          -

             Loss on abandonment and write-off of long-lived assets                                                                                     -                      6,603,028                          -

             Amortization                                                                                                                       3,088,320                      3,394,808                  3,566,269

             Loss on sale of property, plant and equipment                                                                                        828,296                        166,934                    120,224

             Reversal of allowance for doubtful accounts, net                                                                                      (1,904)                       (19,611)                   (57,624)

             Provision for (reversal of) doubtful accounts - other                                                                                110,123                        (10,254)                   475,346
                receivables and prepayments

             Write-down of obsolete inventories                                                                                                         -                        270,929                    451,761

             Deferred tax expense (benefit)                                                                                                     1,127,433                     (2,595,103)                (1,101,171)

             Share-based compensation                                                                                                           4,544,927                      4,896,232                  2,341,783

             Change in fair value of derivative liabilities                                                                                    (1,769,140)                   (11,974,834)                 3,233,288

             Amortization of deferred note issuance cost                                                                                                -                         91,945                    258,753

             Amortization of discount on convertible notes                                                                                              -                      3,503,767                  1,590,740

             Equity in income of an equity method investee                                                                                     (2,665,881)                    (1,858,171)                (1,070,241)

       Change in operating assets and liabilities:

             Accounts receivable                                                                                                                5,689,638                     (6,126,742)                (7,820,523)

             Prepayment and other current assets                                                                                                 (268,498)                      (711,740)                    91,379

             Inventories                                                                                                                       (3,750,200)                   (17,079,263)               (16,026,215)

            Accounts payable                                                                                                                   (2,184,674)                       431,836                    505,407

             Other payables and accrued expenses                                                                                               (3,210,777)                     6,061,066                    190,975

            Accrued interest - noncontrolling interest shareholders                                                                                     -                              -                 (2,086,010)

            Advance from customers                                                                                                             (2,034,138)                     1,140,386                   (429,497)

            Due to related parties                                                                                                                734,037                              -                          -

            Income tax payable                                                                                                                   (904,655)                    (1,512,591)                (1,046,906)
                                                                                                                                                 --------                     ----------                 ----------

    Net cash provided by operating activities                                                                                                  71,097,317                     38,469,919                 38,787,226
                                                                                                                                               ----------                     ----------                 ----------


     CASH FLOWS FROM INVESTING ACTIVITIES:

            Dividends received                                                                                                                  1,109,115                      1,209,880                          -

            Acquisition of a subsidiary, net of cash acquired                                                                                           -                              -                 (4,063,325)

            Payment for property, plant and equipment                                                                                         (13,886,045)                    (7,968,870)               (10,313,432)

            Payment for intangible assets and land use rights                                                                                 (14,059,397)                      (424,971)                (1,474,718)

            Proceeds from sale of property, plant and equipment                                                                                    83,134                         56,709                          -
                                                                                                                                                   ------                         ------                        ---

    Net cash used in investing activities                                                                                                     (26,753,193)                    (7,127,252)               (15,851,475)
                                                                                                                                              -----------                     ----------                -----------




                                                                                                                                         For the Years Ended
                                                                                                                                         -------------------

                                                                                                                                  December 31,                   December 31,               December 31,

                                                                                                                                                     2012                           2011                       2010
                                                                                                                                                     ----                           ----                       ----


    CASH FLOWS FROM FINANCING ACTIVITIES:

             Proceeds from warrants exercised                                                                                                   4,500,000                              -                  1,232,486

             Proceeds from stock option exercised                                                                                                 727,317                        300,000                     97,600

             Acquisition of noncontrolling interest                                                                                                     -                     (7,635,000)                         -

             Proceeds from short term bank loans                                                                                               11,076,100                     18,595,200                  5,917,600

             Repayment of short term bank loans                                                                                               (14,286,800)                   (10,847,200)                (7,397,000)

             Repayment of noncontrolling interest shareholder loan                                                                                      -                              -                 (3,683,377)

             Dividends paid by subsidiaries to noncontrolling interest                                                                         (7,120,693)                   (10,489,504)               (10,446,179)
               shareholders


    Net cash used in financing activities                                                                                                      (5,104,076)                   (10,076,504)               (14,278,870)
                                                                                                                                               ----------                    -----------                -----------


    EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH                                                                                               957,434                      3,204,304                  2,440,536
                                                                                                                                                  -------                      ---------                  ---------


    NET INCREASE IN CASH                                                                                                                       40,197,482                     24,470,467                 11,097,417
                                                                                                                                               ----------                     ----------                 ----------


    Cash and cash equivalents at beginning of year                                                                                             89,411,835                     64,941,368                 53,843,951
                                                                                                                                               ----------                     ----------                 ----------


    Cash and cash equivalents at end of year                                                                                                 $129,609,317                    $89,411,835                $64,941,368
                                                                                                                                             ------------                    -----------                -----------


    Supplemental cash flow information

       Cash paid for income taxes                                                                                                             $14,940,369                    $15,007,206                $15,756,832

       Cash paid for interest expense                                                                                                            $446,381                       $890,312                   $810,643

       Noncash investing and financing activities:

              Convertible notes conversion                                                                          $                                   -                    $12,972,000                 $7,447,095

              Transfer from prepayments and deposits to property, plant                                                                           $38,452                       $959,660                 $1,078,348
                and equipment

             Land use right acquired with prepayments made in prior                                                 $                                   -                       $312,060  $                       -
                periods

             Acquisition of property, plant and equipment included in                                                                            $104,300                        $83,226                 $2,164,449
                payables

             Exercise of warrants that were liability classified                                                                               $3,641,279      $                       -                 $3,045,704

             Restricted cash from government grants for property, plant                                                                        $2,912,145      $                       -  $                       -
                and equipment


                                       RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

                              FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2012 and 2011


                                                  For the three months                 For the three
                                                          ended                        months ended

                                                            12/31/2012                    12/31/2011
                                                            ----------                    ----------

                                                       Net Income                                    Net Income
                                                       ----------                                    ----------

    Adjusted Net Income
     Attributable to the Company
     -Non GAAP                                                            $7,279,757                                $8,623,265

    Diluted EPS - Non GAAP                                                     $0.27                                     $0.33

    Non-cash employee stock
     compensation                                                        $(1,470,795)                              $(1,247,977)

    Loss from change in fair
     value of warrants                                               $             -                               $(3,086,285)

    Impairment loss of goodwill                                      $             -                            $            -

    Loss on abandonment of long-
     lived assets attributable
     to controlling interest                                         $             -                            $            -

    Written-off of raw material
     attributable to controlling
     interest due to closure of
     plasma stations                                                 $             -                                  $345,704

    Net Income Attributable to
     the Company                                                          $5,808,962                                $4,634,707

    Weighted average number of shares used
     in computation of Non GAAP diluted EPS                               27,147,351                                26,425,216


                                                   For the year ended                  For the year
                                                                                            ended

                                                            12/31/2012                    12/31/2011
                                                            ----------                    ----------

                                                       Net Income                       Net Income
                                                       ----------                       ----------

    Adjusted Net Income
     Attributable to the Company
     -Non GAAP                                                           $47,997,976                               $36,502,178

    Diluted EPS - Non GAAP                                                     $1.79                                     $1.37

    Non-cash employee stock
     compensation                                                        $(4,544,927)                              $(4,896,232)

    Impairment loss of goodwill                                      $             -                              $(18,160,281)

    Loss on abandonment of long-
     lived assets attributable
     to controlling interest                                         $             -                               $(3,565,635)

    Written-off of raw material
     attributable to controlling
     interest due to closure of
     plasma stations                                                 $             -                                  $(90,506)

    Interest on the Notes                                            $             -                               $(3,582,648)

    Gain from change in fair
     value of embedded
     conversion option in the
     Notes                                                           $             -                                $6,289,661

    Gain from change in fair
     value of warrants                                                    $1,769,140                                $5,685,173

    Net Income Attributable to
     the Company                                                         $45,222,189                               $18,181,710

    Weighted average number of shares used
     in computation of Non GAAP diluted EPS                               26,839,723                                26,654,662

SOURCE China Biologic Products, Inc.

SOURCE: China Biologic Products, Inc.

China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2012 FY12 Total Sales Up 20.7% to $184.8 Million FY12 Operating Margin Reaching 40.3% FY12 Non-GAAP Net Income Up 31.5% to $48.0 Million

PR Newswire

BEIJING, March 13, 2013 /PRNewswire-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year 2012.

Fourth Quarter 2012 Financial Highlights

  • Total sales in the fourth quarter of 2012 decreased by 4.6% to $34.0 million from $35.7 million in the same quarter of 2011.
  • Gross profit decreased by 5.2% to $23.9 million from $25.2 million in the same quarter of 2011. Gross margin decreased to 70.4% in the fourth quarter of 2012 from 70.8% in the fourth quarter of 2011.
  • Income from operations increased by 41.5% to $13.9 million from $9.8 million in the same quarter of 2011. Operating margin increased to 41.0% in the fourth quarter of 2012 from 27.6% in the same quarter of 2011.
  • Net income attributable to the Company increased by 25.3% to $5.8 million from $4.6 million in the same quarter of 2011. Fully diluted net income per share was $0.21 in the fourth quarter of 2012 as compared to $0.18 in the same quarter of 2011.
  • Non-GAAP adjusted net income attributable to the Company was $7.3 million, representing a 15.6% decrease from $8.6 million in the same quarter of 2011. Non-GAAP adjusted net income per share was $0.27, compared to $0.33 in the same quarter of 2011.

Fiscal Year 2012 Financial Highlights

  • Total sales in 2012 increased by 20.7% to $184.8 million from $153.1 million in 2011.
  • Gross profit in 2012 increased by 17.7% to $126.0 million from $107.1 million in 2011. Gross margin decreased to 68.2% in 2012 from 69.9% in 2011.
  • Income from operations in 2012 increased by 131.2% to $74.5 million from $32.2 million in 2011. Operating margin increased to 40.3% in 2012 from 21.0% in 2011.
  • Net income attributable to the Company increased by 148.7% to $45.2 million from $18.2 million in 2011. Fully diluted net income per share was $1.62 in 2012 as compared to $0.37 in 2011.
  • Non-GAAP adjusted net income attributable to the Company was $48.0 million, representing a 31.5% increase from $36.5 million in 2011. Non-GAAP adjusted net income per share was $1.79, compared to $1.37 in 2011.

Mr. David (Xiaoying) Gao, Chairman and Chief Executive Officer of China Biologic, commented, "We're pleased to see consistently strong demand for our products throughout 2012, which allowed us to enjoy steady top-line annual growth. Our effort over recent years in expanding our sales force and focusing on direct sales to hospitals and inoculation centers has bolstered aspects of our pricing power and reduced our reliance on distributors. We also implemented additional cost control measures since the second half of 2012, resulting in lower selling expenses as a percentage of total sales. Additionally, thanks to enhanced corporate management initiatives, accounts receivable decreased 33.1% year-over-year. Inventories increased 6.1%, in line with production expansion.

"In response to the previously announced delay in construction of our new production facility in Guizhou due to slower-than-expected government approval of land use rights, we implemented an alternative strategy to commence upgrading our current production facility at Guizhou Taibang in June or July 2013 to meet the more stringent  Good Manufacturing Practice ("GMP") standards that take effect by year end. We expect the comprehensive upgrading to our Guizhou Taibang facility to take six to nine months, during which time we will suspend production at this facility. We expect the upgrade of the production facility will be complete in the first half of 2014. To mitigate the negative impact on sales and ensure supply continuity, we have been increasing inventory levels in the past few quarters, adjusting product shipment plans for 2013, and have been and will continue to increase production volume during the first half of 2013."

Mr. Gao continued, "We are also pleased to announce that in January 2013, Shandong Taibang obtained approval from local authorities to establish a new plasma collection station in Cao County, Shandong Province. We expect to obtain operating permits and commence plasma collection operations by the end of June 2013. Cao County is home to a population of 1.6 million and we expect our new plasma station there to ramp up in the next three years, potentially enlarging our collection base in Shandong by 10 to 15 percent."

Fourth Quarter 2012 Financial Performance

Total sales in the fourth quarter of 2012 were $34.0 million, representing a decrease of 4.6% from $35.7 million in the same quarter of 2011. The decrease was mainly due to a human immunoglobulin for intravenous injection ("IVIG") products shipment delay in October when the Company appealed to various regional governments for favorable pricing policies following a price adjustment announcement by the Chinese National Development and Reform Commission ("NDRC") in September 2012. Guizhou and Shandong provincial governments accepted our appeals and approved to lift the tender price ceilings for IVIG products in late October.

Income from operations increased by 41.5% to $13.9 million from $9.8 million in the same quarter of 2011, mainly due to $3.5 million decrease in selling expenses. Operating margin increased to 41.0% in the fourth quarter of 2012 from 27.6% in the same quarter of 2011.

Net income attributable to the Company increased by 25.3% to $5.8 million from $4.6 million in the same quarter of 2011. Fully diluted net income per share was $0.21 in the fourth quarter of 2012 compared to $0.18 in the same quarter of 2011.

Non-GAAP adjusted net income attributable to the Company was $7.3 million, or $0.27 per diluted share, in the fourth quarter of 2012, representing a 15.6% decrease from $8.6 million, or $0.33 per diluted share, in the fourth quarter of 2011. In the fourth quarter of 2011, the Company recorded a loss from change in fair value of warrants of $3.1 million, while no such loss was recorded in the same quarter of 2012.

Fiscal Year 2012 Financial Performances

Total sales in 2012 were $184.8 million, an increase of 20.7% from $153.1 million in 2011. Excluding foreign exchange influence, the increase in sales was primarily attributable to a mix of price and volume increases in plasma-based products, as well as a substantial increase in sales of placenta polypeptide products.

During 2012, most of the Company's approved products recorded price increases. The general price increases for the human albumin products and immunoglobulin product group (other than human hepatitis B immunoglobulin products) were primarily attributable to strong market demand and a shortage of supply following the closure of several plasma collection stations in Guizhou in 2011.

During 2012, human albumin products and human immunoglobulin for intravenous injection ("IVIG") products remained the largest two sales contributors.

  • As a percentage of total sales, human albumin product revenue was 44.6% in 2012 as compared to 54.5% in 2011. Sales volume of human albumin products declined 9.2% over the year.
  • As a percentage of total sales, IVIG revenue was 39.0% in 2012 as compared to 32.3% in 2011. Sales volume of IVIG products increased by 33.6% over the year, mainly due to increased market demand and the Company's ability to ship more product as a result of increased inventory levels built up in the later part of 2011 in anticipation of the demand increase.

Cost of sales increased by 27.9% to $58.8 million in 2012 from $46.0 million in 2011. Cost of sales as a percentage of total sales was 31.8%, as compared to 30.1% in 2011. Volume and percentage increases in cost of sales were mainly due to increased sales activities and increased raw plasma collection costs resulting from higher compensation paid to plasma donors. Gross profit increased by 17.7% to $126.0 million in 2012 from $107.1 million in 2011. Gross margin decreased slightly to 68.2% in 2012 from 69.9% in 2011.

Total operating expenses in 2012 decreased by 31.2% to $51.5 million from $74.9 million in 2011, primarily due to decreased impairment loss. The Company incurred an impairment loss of $24.8 million in 2011, for both goodwill and abandonment of long-lived assets as a result of the closure of several plasma collection stations in Guizhou. There was no impairment loss in 2012. As a percentage of total sales, total operating expenses decreased to 27.9% in 2012 from 48.9% in 2011.

Selling expenses in 2012 decreased to $14.4 million from $14.6 million in 2011. As a percentage of total sales, selling expenses was 7.8%, down from 9.5% in 2011. The decrease in selling expenses as a percentage of sales was primarily due to favorable product pricing and less reliance on distributors as a result of the Company's lengthy efforts at expanding its sales force as well as the Company's sales strategy of focusing on direct sales to hospitals and inoculation centers. The Company has taken additional steps to further control selling expenses since the second half 2012.

General and administrative expenses in 2012 increased by 8.0% to $34.0 million from $31.5 million in 2011. As a percentage of total sales, general and administrative expenses was 18.4% in 2012, down from 20.6% in 2011. The increase in G&A expenses was mainly due to higher payroll expenses and employee benefits, as well as legal expenses related to the disputes among Guizhou Taibang shareholders over the additional capital.

Research and development expenses in 2012 were $3.0 million, as compared to $4.0 million in 2011, representing a decrease of 23.8%. As a percentage of total sales, research and development expenses for the years ended December 31, 2012 and 2011 were 1.6% and 2.6%, respectively. The decrease in R&D expenses was primarily due to the completion of the R&D tests on human coagulation factor VIII ("FVIII") in early 2012.

Income from operations for the year ended December 31, 2012 was $74.5 million, an increase of 131.2% from $32.2 million in the same period of 2011. Operating margin increased to 40.3% in 2012 from 21.0% in 2011.

Income tax expense in 2012 was $15.2 million, as compared to $10.9 million in 2011. The effective income tax rates were 18.7% and 25.8% for the twelve months ended December, 2012 and 2011, respectively.

Net income attributable to the Company increased by 148.7% to $45.2 million in 2012, from $18.2 million in 2011. Net margins were 24.5% and 11.9% for the year ended December 31, 2012 and 2011, respectively. Fully diluted net income per share was $1.62 for the year ended December 31, 2012, as compared to $0.37 for the year ended December 31, 2011.

Non-GAAP adjusted net income attributable to the Company was $48.0 million or $1.79 per diluted share for the year ended December 31, 2012, representing a 31.5% increase from $36.5 million or $1.37 per diluted share in 2011.

Non-GAAP adjusted net income and diluted earnings per share in 2012 excluded an aggregate $1.8 million gain related to the change in the fair value of derivative liabilities, and $4.5 million of non-cash employee share-based compensation expenses.

As of December 31, 2012, the Company had cash and cash equivalents of $129.6 million, compared to $89.4 million as of December 31, 2011.

Net cash provided by operating activities for the year ended December 31, 2012 was $71.1 million, as compared to $38.5 million for the year 2011.

Outlook

For the full year of 2013, the Company expects total sales to be in the range of $195 million to $205 million. This guidance assumes, the production suspension at the Company's Guizhou facility, only organic growth and excludes acquisitions and necessarily assumes no significant adverse price changes during 2013. The Company estimates full year non-GAAP adjusted net income to be in the range of $50 million to $53 million.

This forecast reflects the Company's current and preliminary views, which are subject to change.

Conference Call

The Company will host a conference call at 8:00 am, Eastern Time on Thursday, March 14, 2013, which is 8:00 pm, Beijing Time on March 14, 2013, to discuss fourth quarter and fiscal year 2012 results and answer questions from investors.  Listeners may access the call by dialing:

US:                                         

+1 866 978 9970

International:                     

+852 3027 5500

Hong Kong:                           

3027 5500

China Domestic:               

800 803 6103

China Domestic Mobile:           

400 681 6405



Passcode:                             

 674 477#               

A telephone replay of the call will be available after the conclusion of the conference all through 11:59 pm, Eastern Time on March 20, 2012. The dial-in details are:

US:                                        

+1 866 753 0743

International:                      

+852 3027 5520

Hong Kong:                            

3027 5520

China Domestic:            

800 876 5016


Passcode:                              

138 012#               

About China Biologic Products, Inc.

China Biologic Products, Inc. (Nasdaq: CBPO), is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 plasma-based products through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com.

Non-GAAP Disclosure

This news release contains non-GAAP financial measures that exclude non-cash compensation expenses related to options granted to employees and directors under the Company's 2008 Equity Incentive Plan and changes in the fair value of derivative liabilities, including warrants and derivative instruments (including the conversion option) embedded in the Company's Senior Secured Convertible Notes (after adding back interest related to the convertible notes under the if-converted method). To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information excluding the impact of these items in this release. The Company's management believes that these non-GAAP measures provide investors with a better understanding of how the results relate to the Company's historical performance. A reconciliation of the adjustments to GAAP results appears in the table accompanying this news release. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies.

Safe Harbor Statement

This news release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein, are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect.

Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including its potential inability to achieve the expected operating and financial performance in 2013, potential inability to find alternative sources of plasma, potential inability to increase production at permitted sites, potential inability to mitigate the financial consequences of a temporarily reduced raw plasma supply through cost cutting or other efficiencies, and potential additional regulatory restrictions on its operations and those additional risks and uncertainties discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Contact:    

China Biologic Products, Inc.
Mr. Ming Yin
Vice President
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com

ICR Inc.
Mr. Bill Zima/Rob Koepp
Phone: +86-10-6583-7511 or +1-646-405-5191
E-mail: william.zima@icrinc.com

Financial statements follow

CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

AUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME





For the Years Ended




December 31,



December 31,



December 31,




2012



2011



2010

Sales


$

184,813,495


$

153,092,289


$

139,695,417

Cost of sales



58,835,998



46,017,661



36,951,149

Gross profit



125,977,497



107,074,628



102,744,268











Operating expenses










       Selling expenses



14,421,258



14,595,794



7,372,348

       General and administrative expenses



34,034,360



31,519,824



24,467,495

       Research and development expenses



3,032,719



3,978,233



2,336,126

       Impairment loss of goodwill



-



18,160,281



-

       Loss on abandonment and write-off of long-lived assets



-



6,603,028



-

Income from operations



74,489,160



32,217,468



68,568,299

Other income (expenses)










       Equity in income of an equity method investee



2,665,881



1,858,171



1,070,241

       Change in fair value of derivative liabilities



1,769,140



11,974,834



(3,233,288)

       Interest income



2,910,297



1,356,950



752,317

       Interest expense



(1,269,850)



(4,670,606)



(2,682,482)

       Other income (expense), net



570,511



(453,949)



1,125,972

Total other income (expenses), net



6,645,979



10,065,400



(2,967,240)











Earnings before income tax expense



81,135,139



42,282,868



65,601,059











Income tax expense



15,163,147



10,899,513



13,608,755











Net income



65,971,992



31,383,355



51,992,304











Less: Net income attributable to noncontrolling interest



20,749,803



13,201,645



20,449,421











Net income attributable to China Biologic Products, Inc.


$

45,222,189


$

18,181,710


$

31,542,883











Net income per share of common stock:










       Basic


$

1.73


$

0.73


$

1.34

       Diluted


$

1.62


$

0.37


$

1.30

Weighted average shares used in computation:










       Basic



26,153,540



25,028,796



23,586,506

       Diluted



26,839,723



26,654,662



24,176,432











Net income


$

65,971,992


$

31,383,355


$

51,992,304











Other comprehensive income :










Foreign currency translation adjustment, net of nil income taxes



1,735,492



6,846,721



5,177,515











Comprehensive income



67,707,484



38,230,076



57,169,819











Less: Comprehensive income attributable to noncontrolling interest



21,163,655



15,320,805



21,831,352











Comprehensive income attributable to China Biologic Products, Inc.


$

46,543,829


$

22,909,271


$

35,338,467

 

CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

AUDITED CONDENSED CONSOLIDATED BALANCE SHEETS




December 31,



December 31,



2012



2011

ASSETS







Current Assets







   Cash and cash equivalents


$

129,609,317


$

89,411,835

   Accounts receivable, net of allowance for doubtful accounts



11,206,244



16,757,368

   Inventories



75,679,173



71,338,590

   Prepayments and other current assets



5,664,919



6,185,720

         Total Current Assets



222,159,653



183,693,513








Property, plant and equipment, net



51,325,177



43,329,463

Intangible assets, net



3,541,582



6,520,671

Land use rights, net



5,818,709



5,487,343

Deposits related to land use rights



14,752,574



1,504,568

Restricted cash



2,912,145



-

Equity method investment



10,537,310



8,357,017

           Total Assets


$

311,047,150


$

248,892,575








LIABILITIES AND STOCKHOLDERS' EQUITY







Current liabilities







   Short-term bank loans


$

7,935,000


$

11,018,000

   Accounts payable



2,908,624



4,996,463

   Due to related parties



4,081,624



3,319,938

   Other payables and accrued expenses



25,423,349



32,851,707

   Advance from customers



2,857,420



4,852,125

   Income tax payable



4,513,075



5,373,633

   Derivative liabilities - warrants



-



5,410,419

         Total Current Liabilities



47,719,092



67,822,285

Deferred income



2,912,145



-

Other liabilities



2,996,749



2,029,249

         Total Liabilities



53,627,986



69,851,534








Stockholders' Equity







   Common stock: par value $0.0001; 100,000,000 shares authorized; 26,629,615 and 25,601,125 shares issued and outstanding at December 31, 2012 and 2011, respectively



2,663



2,560

   Additional paid-in capital



62,251,731



48,838,311

   Retained earnings



119,143,000



73,920,811

   Accumulated other comprehensive income



14,072,322



12,750,682

   Total equity attributable to China Biologic Products, Inc.



195,469,716



135,512,364








   Noncontrolling interest



61,949,448



43,528,677








         Total Stockholders' Equity



257,419,164



179,041,041








   Commitments and contingencies



-



-








         Total Liabilities and Stockholders' Equity


$

311,047,150


$

248,892,575

 

CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

AUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS





For the Years Ended




December 31,



December 31,



December 31,




2012



2011



2010

CASH FLOWS FROM OPERATING ACTIVITIES:










Net income


$

65,971,992


$

31,383,355


$

51,992,304

Adjustments to reconcile net income to net cash provided by operating activities:










         Depreciation



5,792,418



4,253,661



3,607,184

         Impairment loss of goodwill



-



18,160,281



-

         Loss on abandonment and write-off of long-lived assets



-



6,603,028



-

         Amortization



3,088,320



3,394,808



3,566,269

         Loss on sale of property, plant and equipment



828,296



166,934



120,224

         Reversal of allowance for doubtful accounts, net



(1,904)



(19,611)



(57,624)

         Provision for (reversal of) doubtful accounts - other
            receivables and prepayments



110,123



(10,254)



475,346

         Write-down of obsolete inventories



-



270,929



451,761

         Deferred tax expense (benefit)



1,127,433



(2,595,103)



(1,101,171)

         Share-based compensation



4,544,927



4,896,232



2,341,783

         Change in fair value of derivative liabilities



(1,769,140)



(11,974,834)



3,233,288

         Amortization of deferred note issuance cost



-



91,945



258,753

         Amortization of discount on convertible notes



-



3,503,767



1,590,740

         Equity in income of an equity method investee



(2,665,881)



(1,858,171)



(1,070,241)

   Change in operating assets and liabilities:










         Accounts receivable



5,689,638



(6,126,742)



(7,820,523)

         Prepayment and other current assets



(268,498)



(711,740)



91,379

         Inventories



(3,750,200)



(17,079,263)



(16,026,215)

        Accounts payable



(2,184,674)



431,836



505,407

         Other payables and accrued expenses                                     



(3,210,777)



6,061,066



190,975

        Accrued interest - noncontrolling interest shareholders



-



-



(2,086,010)

        Advance from customers



(2,034,138)



1,140,386



(429,497)

        Due to related parties



734,037



-



-

        Income tax payable



(904,655)



(1,512,591)



(1,046,906)

Net cash provided by operating activities



71,097,317



38,469,919



38,787,226











 CASH FLOWS FROM INVESTING ACTIVITIES:










        Dividends received



1,109,115



1,209,880



-

        Acquisition of a subsidiary, net of cash acquired



-



-



(4,063,325)

        Payment for property, plant and equipment



(13,886,045)



(7,968,870)



(10,313,432)

        Payment for intangible assets and land use rights



(14,059,397)



(424,971)



(1,474,718)

        Proceeds from sale of property, plant and equipment



83,134



56,709



-

Net cash used in investing activities



(26,753,193)



(7,127,252)



(15,851,475)


































For the Years Ended




December 31,



December 31,



December 31,




2012



2011



2010











CASH FLOWS FROM FINANCING ACTIVITIES:










         Proceeds from warrants exercised



4,500,000



-



1,232,486

         Proceeds from stock option exercised



727,317



300,000



97,600

         Acquisition of noncontrolling interest



-



(7,635,000)



-

         Proceeds from short term bank loans



11,076,100



18,595,200



5,917,600

         Repayment of short term bank loans



(14,286,800)



(10,847,200)



(7,397,000)

         Repayment of noncontrolling interest shareholder loan



-



-



(3,683,377)

         Dividends paid by subsidiaries to noncontrolling interest
           shareholders



(7,120,693)



(10,489,504)



(10,446,179)

Net cash used in financing activities



(5,104,076)



(10,076,504)



(14,278,870)











EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH



957,434



3,204,304



2,440,536











NET INCREASE IN CASH



40,197,482



24,470,467



11,097,417











Cash and cash equivalents at beginning of year



89,411,835



64,941,368



53,843,951











Cash and cash equivalents at end of year


$

129,609,317


$

89,411,835


$

64,941,368











Supplemental cash flow information










   Cash paid for income taxes


$

14,940,369


$

15,007,206


$

15,756,832

   Cash paid for interest expense


$

446,381


$

890,312


$

810,643

   Noncash investing and financing activities:










          Convertible notes conversion


$

-


$

12,972,000


$

7,447,095

          Transfer from prepayments and deposits to property, plant
            and equipment


$

38,452


$

959,660


$

1,078,348

         Land use right acquired with prepayments made in prior
            periods


$

-


$

312,060


$

-

         Acquisition of property, plant and equipment included in
            payables


$

104,300


$

83,226


$

2,164,449

         Exercise of warrants that were liability classified


$

3,641,279


$

-


$

3,045,704

         Restricted cash from government grants for property, plant
            and equipment


$

2,912,145


$

-


$

-

 

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2012 and 2011




For the three months ended


For the three months ended



12/31/2012


12/31/2011



Net Income



Net Income

Adjusted Net Income Attributable to the Company - Non GAAP

$

7,279,757



$

8,623,265

Diluted EPS - Non GAAP


$

0.27



$

0.33

Non-cash employee stock compensation


$

(1,470,795)



$

(1,247,977)

Loss from change in fair value of warrants

$

-



$

(3,086,285)

Impairment loss of goodwill

$

-



$

-

Loss on abandonment of long-lived assets attributable to controlling interest

$

-



$

-

Written-off of raw material attributable to controlling interest due to closure of plasma stations

$

-



$

345,704

Net Income Attributable to the Company

$

5,808,962



$

4,634,707

Weighted average number of shares used in computation of Non GAAP diluted EPS


27,147,351




26,425,216











For the year ended


For the year ended



12/31/2012


12/31/2011



Net Income


Net Income

Adjusted Net Income Attributable to the Company - Non GAAP

$

47,997,976



$

36,502,178

Diluted EPS - Non GAAP


$

1.79



$

1.37

Non-cash employee stock compensation


$

(4,544,927)



$

(4,896,232)

Impairment loss of goodwill

$

-



$

(18,160,281)

Loss on abandonment of long-lived assets attributable to controlling interest

$

-



$

(3,565,635)

Written-off of raw material attributable to controlling interest due to closure of plasma stations

$

-



$

(90,506)

Interest on the Notes


$

-



$

(3,582,648)

Gain from change in fair value of embedded conversion option in the Notes

$

-



$

6,289,661

Gain from change in fair value of warrants

$

1,769,140



$

5,685,173

Net Income Attributable to the Company

$

45,222,189



$

18,181,710

Weighted average number of shares used in computation of Non GAAP diluted EPS


26,839,723




26,654,662

 

SOURCE China Biologic Products, Inc.

Web Site: http://www.chinabiologic.com


print email rss
© 2014 China Biologic Products, Inc. All Rights Reserved.